The lancet oncology
-
The lancet oncology · Aug 2014
Randomized Controlled Trial Multicenter Study Comparative StudyRilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Dysregulation of the hepatocyte growth factor (HGF)/MET pathway promotes tumour growth and metastasis. Rilotumumab is a fully human, monoclonal antibody that neutralises HGF. We aimed to assess the safety, efficacy, biomarkers, and pharmacokinetics of rilotumumab combined with epirubicin, cisplatin, and capecitabine (ECX) in patients with advanced gastric or oesophagogastric junction cancer. ⋯ Amgen Inc.
-
The lancet oncology · Aug 2014
Randomized Controlled Trial Multicenter Study Comparative StudyCombination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
Addition of a MEK inhibitor to a BRAF inhibitor enhances tumour growth inhibition, delays acquired resistance, and abrogates paradoxical activation of the MAPK pathway in preclinical models of BRAF-mutated melanoma. We assessed the safety and efficacy of combined BRAF inhibition with vemurafenib and MEK inhibition with cobimetinib in patients with advanced BRAF-mutated melanoma. ⋯ F Hoffmann-La Roche/Genentech.
-
The lancet oncology · Aug 2014
Randomized Controlled Trial Multicenter StudyMEK1/2 inhibition delays progression of uveal melanoma.
-
The lancet oncology · Aug 2014
Randomized Controlled Trial Comparative StudyPoor results for everolimus in patients with liver cancer.
-
The lancet oncology · Aug 2014
Randomized Controlled Trial Comparative StudyMethylprednisolone in patients with cancer using opioids.